Premium
Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost‐effective and safer treatment of advanced follicular lymphoma
Author(s) -
McClanahan F.,
Hielscher T.,
Rieger M.,
Hensel M.,
Bentz M.,
SchmidtWolf I.,
Käbisch A.,
Salwender H.,
Dürk H.,
Staiger H.,
Mandel T.,
Neben K.,
Hillengass J.,
Leo E.,
Krämer A.,
Ho A.D.,
WitzensHarig M.
Publication year - 2012
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23286
Subject(s) - rituximab , medicine , randomized controlled trial , follicular lymphoma , chop , clinical endpoint , oncology , clinical trial , lymphoma